AbbVie Inc. (ABBV)
| Market Cap | 375.50B |
| Revenue (ttm) | 58.33B |
| Net Income (ttm) | 3.72B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.10 |
| PE Ratio | 101.21 |
| Forward PE | 16.20 |
| Dividend | $6.56 (3.08%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 4,465,100 |
| Open | 212.55 |
| Previous Close | 213.00 |
| Day's Range | 211.00 - 214.34 |
| 52-Week Range | 163.81 - 218.66 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 216.10 (+1.67%) |
| Earnings Date | Oct 29, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $216.1, which is an increase of 1.67% from the latest price.
News
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill. , Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EP...
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
NORTH CHICAGO, Ill. , Sept. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025.
How To Invest $100,000 In A Near-Perfect Strategy Portfolio
Market timing is futile; a disciplined, diversified, and rules-based approach is essential for long-term investing success. A Near-Perfect Strategy portfolio aims for consistent income, growth, and lo...
AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
President Trump's threats against Big Pharma do not prevent AbbVie shares from rising. AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and S...
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.
Best Dividend Aristocrats For September 2025
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...
AbbVie: Plenty Of Positives
AbbVie has had a good August, with double digit MoM gains after seeing weakness for six months. Factors like an EU-US deal on pharmaceuticals, recent results, improved guidance, positive outcomes in ...
AbbVie Is A Top Biotech Pick
Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential...
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion
AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion.
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is...
Best Dividend Kings: August 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...
AbbVie Investors Beware: Strong Growth Potential, Rising Risks
AbbVie has delivered strong total returns and dividend growth over time. Additionally, it enjoys strong growth prospects. However, it also faces significant uncertainty and risks.
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
In the second replicate study (Study 1) of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with severe ...
AbbVie Completes Acquisition of Capstan Therapeutics
Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform ...
SkinMedica® Unveils Its Newest Hydration Hero
By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica® introduces a next generation amino acid–based cleanser: HA5® Hydra Collagen Hydrating Foaming Cleanser. IRVINE, Calif , Aug. 19, 2025...
My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys
July saw strong market gains, especially in tech, but finding bargains is tough as indices approach all-time highs. I focused July investments on high-yield BDCs like OBDC, MFIC, and BXSL, maintaining...
AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition
AbbVie Inc.'s Q2 2025 results highlight Skyrizi and Rinvoq's dominance, replacing Humira and driving impressive revenue growth, with both drugs exceeding expectations. The company's aggressive neurosc...
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie's previously announced commi...
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...
Get Ready, JUVÉDERM® Day is Calling!
Allergan Aesthetics Celebrates Third Annual JUVÉDERM® Day with BOGO Gift Cards and $10,000 Sweepstakes Join Allē Today to Take Advantage of Limited-Time Offers, While Supplies Last IRVINE, Calif. , Au...
Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
Nine women from across the U.S. share their personal experiences with breast augmentation and reconstruction with Natrelle® – celebrating confidence, self-expression, and restoration. IRVINE, Calif.
The Big 3: ABBV, ETSY, VRT
Mike Shorr (@ProsperTradingAcademy) walks through a pair of stocks he sees set up for a swing breakout: AbbVie (ABBV) and Etsy Inc. (ETSY). For both, he demonstrates an example options trade using a c...
AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
On Thursday, AbbVie Inc. ABBV reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.